Department of Veterinary Clinical Sciences, The Royal Veterinary College, Hatfield, UK.
Equine Vet J. 2012 Jan;44(1):25-32. doi: 10.1111/j.2042-3306.2011.00363.x. Epub 2011 May 26.
Mesenchymal stem (progenitor; stromal) cell (MSC) therapy has gained popularity for the treatment of equine tendon injuries but without reports of long-term follow-up.
To evaluate the safety and reinjury rate of racehorses after intralesional MSC injection in a large study of naturally occurring superficial digital flexor tendinopathy and to compare these data with those published for other treatments.
Safety was assessed clinically, ultrasonographically, scintigraphically and histologically in a cohort of treated cases: 141 client-owned treated racehorses followed-up for a minimum of 2 years after return to full work. Reinjury percentages were compared to 2 published studies of other treatments with similar selection criteria and follow-up. The number of race starts, discipline, age, number of MSCs injected and interval between injury and treatment were analysed.
There were no adverse effects of the treatment with no aberrant tissue on histological examination. The reinjury percentage of all racehorses with follow-up (n = 113) undergoing MSC treatment was 27.4%, with the rate for flat (n = 8) and National Hunt (n = 105) racehorses being 50 and 25.7%, respectively. This was significantly less than published for National Hunt racehorses treated in other ways. No relationship between outcome and age, discipline, number of MSCs injected or injury to implantation interval was found.
Whilst recognising the limitations of historical controls, this study has shown that MPC implantation is safe and appears to reduce the reinjury rate after superficial digital flexor tendinopathy, especially in National Hunt racehorses.
This study has provided evidence for the long-term efficacy of MSC treatment for tendinopathy in racehorses and provides support for translation to human tendon injuries.
间充质干细胞（祖细胞；基质）治疗在治疗马的腱损伤方面越来越受欢迎，但没有长期随访的报道。
在一项关于自然发生的浅层屈肌腱病的大型研究中，评估经皮内注射间充质干细胞治疗赛马的安全性和再损伤率，并将这些数据与其他治疗方法的报道进行比较。
对治疗组的病例进行临床、超声、闪烁扫描和组织学评估：141 匹经客户拥有并接受治疗的赛马在完全恢复工作后至少随访 2 年。将再损伤率与其他两种具有相似选择标准和随访的治疗方法的 2 项已发表研究进行比较。分析赛马的起跑次数、学科、年龄、注射的间充质干细胞数量以及损伤和治疗之间的时间间隔。
治疗没有不良反应，组织学检查未见异常组织。所有接受 MSC 治疗并随访（n=113）的赛马再损伤率为 27.4%，平地赛（n=8）和国家狩猎赛（n=105）赛马的再损伤率分别为 50%和 25.7%。这明显低于其他方式治疗的国家狩猎赛赛马的报道。未发现结局与年龄、学科、注射间充质干细胞数量或损伤至植入间隔时间之间的关系。
尽管认识到历史对照的局限性，但本研究表明，MPC 植入是安全的，似乎可以降低浅层屈肌腱病后的再损伤率，尤其是在国家狩猎赛赛马中。
本研究为 MSC 治疗赛马腱病的长期疗效提供了证据，并为向人类腱损伤的转化提供了支持。
